Merck Sharp + Dohme Corp.

Wenlang Fu

Amjad Ali

John D Schreier

Sung-Sau So

Robert R Wilkening

Ping Liu

Phieng Siliphaivanh

John S Debenham

Izzat Tiedje Raheem

Rongze Kuang

Anthony K Ogawa

Petr Vachal

Qinglin Pu

Lan Wei

Jacqueline D Hicks

Dexi Yang

Zhiqiang Guo

Kenneth Ellsworth

Meng Yang

Tianying Jian

Ming Wang

Jun Wang

Matthew Lombardo

Brett A Hopkins

Sulagna Sanyal

Xin Yan

Daniel A Tatosian

Peter Nizner

Meredeth A Mcgowan

George Madalin Giambasu

Ning Qi

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

IL4I1 inhibitors and methods of use

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral oxime phosphoramide compounds

Growing community of inventors

Madison, NJ, United States of America

Wenlang Fu